Ekert H, Price D A, Lane J L, Dean F L
Aust N Z J Med. 1979 Jun;9(3):241-4. doi: 10.1111/j.1445-5994.1979.tb04130.x.
In four children with haemophilia A and antibodies to factor VIII, 18 bleeding episodes were randomized for treatment with factor VIII concentrate (30 units/kg) and 18 for treatment with a prothrombin-complex concentrate (prothrombinex) given in a dose of 30 units of factor IX/kg. Treatment with prothrombinex was associated with a better clinical response, a significantly greater shortening of the kaolin partial thromboplastin time and significantly lower incidence of post-infusion increase of levels of factor VIII antibodies. Although treatment with factor VIII concentrate was clinically successful in 15 episodes, treatment failures occurred in three instances leading to parental request for withdrawal from study in two families.
在4名患有A型血友病且体内存在抗凝血因子VIII抗体的儿童中，将18次出血发作随机分组，一组用凝血因子VIII浓缩剂（30单位/千克）治疗，另一组用凝血酶原复合物浓缩剂（凝血酶原复合物）治疗，剂量为每千克体重含30单位的凝血因子IX。使用凝血酶原复合物治疗的临床反应更好，高岭土部分凝血活酶时间显著缩短，输注后凝血因子VIII抗体水平升高的发生率显著降低。虽然凝血因子VIII浓缩剂治疗在15次发作中取得了临床成功，但有3例治疗失败，导致两个家庭的家长要求退出研究。
